Efficacy of Dose Intensification in Patients With Non-metastatic Ewing

Status Completed

Clinical Trial Summary

Controlled, randomized phase III study, with the intent of optimizing the treatment of not metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs intensive treatment. Both arms will receive an induction treatment followed by surgery (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on the basis of the response to the induction treatment (good or poor)

Clinical Trial Description

Eligible patients with non metastatic Ewing's Sarcoma will be randomized into 2 different arms: standard treatment arm A (based on the ISG/SSG III protocol) or into the experimental arm B(chemotherapy with dose intensification and shorter length of treatment). Both arm will receive an induction treatment with higher dose intensity of doxorubicin and ifosfamide in Arm B. After the induction treatment all the patient will undergo to local treatment (surgery and/or radiotherapy)that will be followed by a maintenance therapy. The maintenance therapy will be different for both arms and, within each arm, on the basis of the response (histologically evaluated) of the pre-local treatment therapy. Maintenance for Arm A: Poor responders will undergo to stem cells apheresis and their reinfusion after treatment with high doses of Busulfan and Melphalan 25 weeks. Good responders will receive a 6 drugs maintenance treatment for 37 weeks (as per standard ISG/SSG III protocol) Maintenance for Arm B: Poor responders will undergo to stem cells apheresis and their reinfusion after an intensified treatment with high doses of Busulfan and Melphalan (25 weeks). Good responders will receive a maintenance treatment for 25 weeks The primary aim of the study is to assess the Event Free Survival (EFS) that is expected to be similar in both arms The secondary objectives are: To assess if the induction treatment in Arm B is able to increase the percentage of good responders compared to those who receive standard treatment. To assess the toxicity and the Quality of Life related to the chemotherapy treatment ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02063022
Study type	Interventional
Source	Italian Sarcoma Group
Contact
Status	Completed
Phase	Phase 3
Start date	January 22, 2009
Completion date	April 14, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01734863` - Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients	Phase 3
Completed	`NCT01674101` - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy	N/A
Completed	`NCT02736565` - Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma	Phase 1
Completed	`NCT00563680` - QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors	Phase 2
Completed	`NCT00987636` - Study in Localized and Disseminated Ewing Sarcoma	Phase 3
Terminated	`NCT00038142` - Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients	Phase 2
Completed	`NCT02890758` - Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803	Phase 1
Completed	`NCT01583543` - Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma	Phase 2
Terminated	`NCT01313884` - Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma	Phase 2
Completed	`NCT01696669` - Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults	Phase 2
Completed	`NCT00004853` - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy	Phase 1
Terminated	`NCT00568464` - Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)	Phase 2
Completed	`NCT00001686` - Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
Completed	`NCT00492141` - Aerosol L9-NC and Temozolomide in Ewing's Sarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT00541411` - Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma	N/A
Completed	`NCT01598454` - Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides	Phase 1
Recruiting	`NCT03442465` - Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Completed	`NCT02511132` - A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma	Phase 2
Completed	`NCT00923650` - Informed Consent in Pediatric Cancer Trials	N/A
Completed	`NCT01962103` - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma — EW-1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms